Donaldson's Univercells Technologies Expands Evaluation Agreement With University Of Pennsylvania's Gene Therapy Program; Aims To Determine Scalability Of Gene Therapy Manufacturing Using Univercells' Bioreactors
Portfolio Pulse from Benzinga Newsdesk
Donaldson's Univercells Technologies has expanded its evaluation agreement with the University of Pennsylvania's Gene Therapy Program to determine the scalability of gene therapy manufacturing using Univercells' bioreactors. The program is led by Dr. James M. Wilson at the Perelman School of Medicine.
July 16, 2024 | 1:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Donaldson's Univercells Technologies has expanded its agreement with the University of Pennsylvania's Gene Therapy Program to evaluate the scalability of gene therapy manufacturing using its bioreactors.
The expansion of the evaluation agreement with a prestigious institution like the University of Pennsylvania could lead to significant advancements in gene therapy manufacturing, potentially boosting Donaldson's market position and stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80